Reports

220 Results (Page 5 of 9)

Italy Markets Research Reports

Rare Diseases

Italy Acute Myeloid Leukemia Market Analysis

Italy Acute Myeloid Leukemia Market is projected to grow from $xx Mn in 2023 to $xx Mn by 2030, registering a CAGR of xx% during the forecast period of 2023-30. The ageing population, higher drug approval rates, the designation of acute myeloid leukaemia as an orphan disease, and rising healthcare costs are anticipated to drive the market. One of the factors accelerating the market's growth is the technological advancement made possible by the capacity to recognise damaged cells. Major global players in Acute Myeloid Leukemia Market are Ambit Biosciences Corporation, Genzyme Corporation, Celgene Corporation, Clavis Pharma ASA, Sunesis Pharmaceuticals, Cephalon, Bristol-Myers Squibb, Novartis International AG, GlaxoSmithKline.

PUBLISHED: Jul, 2023 | FORMAT: PPT | LAST UPDATED: Jul, 2023 | PRICE: $3999

Rare Diseases

Italy ADPKD (Autosomal dominant polycystic kidney disease) Drugs Market Analysis

Italy ADPKD (Autosomal dominant polycystic kidney disease) Drugs Market is projected to grow from $xx Mn in 2023 to $xx Mn by 2030, registering a CAGR of xx% during the forecast period of 2023-30. The market for drugs to treat polycystic kidney disease is driven by an increase in patients who require dialysis or renal failure. A significant factor influencing the growth rate of the polycystic kidney disease (PKD) drugs market is the rise in healthcare spending, which helps to improve its infrastructure. Major global players in ADPKD (Autosomal dominant polycystic kidney disease) Drugs Market are Otsuka Pharmaceutical Co., Ltd., Regulus Therapeutics, Palladio Biosciences, Reata Pharmaceuticals, Inc., Galapagos NV, AceLink Therapeutics, Inc., Exelixis, Inc, XORTX Therapeutics Inc., Sanofi S.A., PanoTherapeutics, Inc.

PUBLISHED: Jul, 2023 | FORMAT: PPT | LAST UPDATED: Jul, 2023 | PRICE: $3999

Rare Diseases

Italy Adrenoleukodystrophy (ALD) Drugs Market Analysis

Italy Adrenoleukodystrophy (ALD) Drugs Market is projected to grow from $xx Mn in 2023 to $xx Mn by 2030, registering a CAGR of xx% during the forecast period of 2023 ? 2030. Drivers of acromegaly market are increasing cases of the disorder which in turn increased awareness and government focus motivated financial support to R&D. Poxel SA, Bluebird Bio Inc.,Viking Technologies, Minoryx Therapeutics sl., Apteeus SAS, Ashvattha Therapeutics LLC, NeuroVia Company, Autobahn Therapeutics Inc., Aldagen Inc., Celularity Inc., Imstem Biotechnology Inc., MedDay SA, and Orpheris Inc. are major competitors in the Global Adrenoleukodystrophy (ALD) drugs Market.

PUBLISHED: Jul, 2023 | FORMAT: PPT | LAST UPDATED: Jul, 2023 | PRICE: $3999

Rare Diseases

Italy Ankylosing Spondylitis Drugs Market Analysis

Italy Ankylosing Spondylitis Drugs market is projected to grow from $xx Mn in 2023 to $xx Mn by 2030, registering a CAGR of xx% during the forecast period of 2023 ? 2030. Ankylosing spondylitis is a kind of arthritis that affects connective tissues. The sacroiliac joints, which connect the spine to the pelvis, become inflamed, but in extreme situations, the spine's bones might fuse together and become very inflexible. A rough estimate of 1.1 Mn Americans, or one out of every 200 adults, are impacted. Abbvie, Amgen, Eli Lilly, Janssen, Merck, Pfizer, Novartis, UCB, and many other leading companies are active in the ankylosing spondylitis global market. To increase their market share, these businesses engage in strategic alliances and acquisitions in addition to concentrating on research and development to bring novel therapies to market.

PUBLISHED: Jul, 2023 | FORMAT: PPT | LAST UPDATED: Jul, 2023 | PRICE: $3999

Rare Diseases

Italy Autoimmune Hemolytic Anemia Drugs Market Analysis

Italy Autoimmune Hemolytic Anemia Drugs Market is projected to grow from $xx Mn in 2023 to $xx Mn by 2030, registering a CAGR of xx% during the forecast period of 2023-30. A rise in the prevalence of certain autoimmune illnesses and malignancies, as well as increased funding for research into innovative interventions and growing demand for novel therapies, are all contributing to an increase in the market for medications to treat autoimmune hemolytic anaemia. Major global players in Autoimmune Hemolytic Anemia Drugs Market are F. Hoffmann-La Roche Ltd, Teva Pharmaceutical Industries Ltd, Zydus Cadila, Vertice Pharma, Concord Biotech, Alkem Labs, Dr. Reddy's Laboratories Ltd, Jubilant Life Sciences Ltd, Strides Pharma Science Limited, Mylan N.V., Novartis AG, Sanofi, Rigel Pharmaceuticals Inc, Incyte Corporation, Alexion Pharmaceuticals, Apellis Pharmaceuticals.

PUBLISHED: Jul, 2023 | FORMAT: PPT | LAST UPDATED: Jul, 2023 | PRICE: $3999

Rare Diseases

Italy CDKL5 deficiency disorder (CDD) market Analysis

Italy CDKL5 deficiency disorder Market is projected to grow from $xx Mn in 2023 to $xx Mn by 2030, registering a CAGR of xx% during the forecast period of 2023 - 2030. The market for CDKL5 deficiency disorder is expanding as a result of increase in global prevalence of CDKL5 deficiency disorder and increase in awareness about neurological diseases. In addition, high expenditure on healthcare and genetic testing, growing demand for targeted therapies, increase in R&D spending for the discovery of novel pharmaceuticals are other reasons . This demand is fueling the development of better pharmaceuticals and other treatment methods for the accurate treatment of CDKL5 deficiency disorder. Some of the key players in the global CDKL5 deficiency disorder market include Marinus pharmaceuticals, REGENXBIO, Zogenix, PTC therapeutics and Ovid therapeutics/ Takeda

PUBLISHED: Jul, 2023 | FORMAT: PPT | LAST UPDATED: Jul, 2023 | PRICE: $3999

Rare Diseases

Italy Colorectal Cancer Drugs Market Analysis

Italy Colorectal Cancer drugs Market is projected to grow from $xx Mn in 2023 to $xx Mn by 2030, registering a CAGR of xx% during the forecast period of 2023 - 2030. The market for colorectal cancer drugs is expanding due to various reasons like increase incidence and prevalence of colorectal cancer cases, increase awareness about the disease, globally ageing population. Mortality due to colorectal cancer, rising medical tourism in developing countries and benefits offered by generic medicines are other reasons. Bristol-Myer Squibb, Merck, Sanofi, Eli Lilly, Bayer are the top key market players in Global Colorectal Cancer drugs Market.

PUBLISHED: Jul, 2023 | FORMAT: PPT | LAST UPDATED: Jul, 2023 | PRICE: $3999

Rare Diseases

Italy Complex Regional Pain Syndrome (CRPS) Market Analysis

Italy Complex regional pain syndrome (CRPS) Market is projected to grow from $xx Mn in 2023 to $xx Mn by 2030, registering a CAGR of xx% during the forecast period of 2023 - 2030. The market for Complex regional pain syndrome (CRPS) is expanding as a result of rising incidence of complex regional pain syndrome and the growing number of patients suffering from chronic pain and failing back syndrome. Growth in R&D spending by both commercial and public institutions, as well as favourable government legislation and increase in product launches are other factors increasing market growth. Ovid therapeutics, Astra Zeneca, Abbott, GSK, Viatris and Johnson & Johnson Services are the top key market players in Global Complex regional pain syndrome (CRPS) market.

PUBLISHED: Jul, 2023 | FORMAT: PPT | LAST UPDATED: Jul, 2023 | PRICE: $3999

Rare Diseases

Italy Cutaneous T-cell Lymphoma Market Analysis

Italy Cutaneous T-cell Lymphoma Market is projected to grow from $xx Mn in 2023 to $xx Mn by 2030, registering a CAGR of xx% during the forecast period of 2023 - 2030. The market for Cutaneous T-cell Lymphoma is expanding as a result of increase in strategic investments by private as well as public agencies for Research and development of new drugs and therapies in the market , increase in product approval along with increasing manufacturing capacities, increasing trend towards adoptive therapies rather than small molecule and protein based treatment. All these factors are expected to increase the market growth. Bristol-Myers Squibb Company, Merck & Co., Novartis, Johnson and Johnson private limited, GlaxoSmithKline plc are the top key market players operating in the global cutaneous T-cell Lymphoma market.

PUBLISHED: Jul, 2023 | FORMAT: PPT | LAST UPDATED: Jul, 2023 | PRICE: $3999

Rare Diseases

Italy Cystic Fibrosis Drugs Market Analysis

Italy Cystic Fibrosis Drugs Market is projected to grow from $xx Mn in 2023 to $xx Mn by 2030, registering a CAGR of xx% during the forecast period of 2023 - 2030. The market for Cystic Fibrosis Drugs is expanding as a result of rising incidence and prevalence of cystic fibrosis globally, existance of potential pipeline candidates, methods of early detection and treatment, growing awareness of the potential threat caused by cystic fibrosis and rising use of pharmacological therapy. Vertex Pharmaceuticals, AbbVie, Viatris, Nestl? Health Science, Teva pharmaceuticals are the top key market players operating in the global cystic fibrosis market.

PUBLISHED: Jul, 2023 | FORMAT: PPT | LAST UPDATED: Jul, 2023 | PRICE: $3999

Rare Diseases

Italy Duchenne Muscular Dystrophy (DMD) Drugs Market Analysis

Italy Cystic Fibrosis Drugs Market is projected to grow from $xx Mn in 2023 to $xx Mn by 2030, registering a CAGR of xx% during the forecast period of 2023 - 2030. The market for Duchenne Muscular Dystrophy (DMD) Drugs is expanding as a result of rising incidence and prevalence of duchenne muscular dystrophy, improved diagnosis of the disease, emergence of mutation specific and gene specific therapies, favourable government initiatives and supportive regulatory environments in various countries. Sarepta therapeutics, PTC therapeutics, Santhera pharmaceuticals are the top key market players operating in the Cystic fibrosis drugs market.

PUBLISHED: Jul, 2023 | FORMAT: PPT | LAST UPDATED: Jul, 2023 | PRICE: $3999

Rare Diseases

Italy Eosinophilic Esophagitis Drugs Market Analysis

Italy Eosinophilic Esophagitis Drugs Market is projected to grow from $xx Mn in 2023 to $xx Mn by 2030, registering a CAGR of xx% during the forecast period of 2023 - 2030. The market for eosinophilic esophagitis drugs is growing rapidly as a result of increase in awareness programs for disorders associated with eosinophils, development and use of new generation of non- invasive diagnostic tools, increase in use of eosinophilic esophagitis drugs and therapies for the treatment of various inflammations by physicians worldwide, increase in research and development activities and clinical trials conducted by pharmaceutical firms, promising eosinophilic esophagitis pipeline. Astra Zeneca, Sanofi, Cipla, Glaxo smith kline ,Arena pharmaceuticals, Takeda pharmaceuticals are the top key market players operating in the global eosinophilic esophagitis drugs market.

PUBLISHED: Jul, 2023 | FORMAT: PPT | LAST UPDATED: Jul, 2023 | PRICE: $3999

Rare Diseases

Italy Erythropoietin Drugs Market Analysis

Italy Erythropoietin Drugs market is projected to grow from $xx Mn in 2023 to $xx Mn by 2030, registering a CAGR of xx% during the forecast period of 2023 - 2030. The market for erythropoietin drugs is growing rapidly as a result of rising prevalence of chronic diseases like kidney diseases, cancer, HIV globally and requirements of erythropoietin drugs in these diseases, rise in anemia in patients, growing awareness about blood related disorders like anemia, patent expiration of innovator drugs and development of generic drugs, development of erythropoietin biosimilars and therapeutic benefits offered by erythropoietin drugs. Johnson & Johnson, Inc., LG Life Sciences Ltd., Ranbaxy Laboratories Ltd., Sun Pharmaceutical Industries Ltd., Teva Pharmaceutical Industries Ltd., Dr. Reddy's Laboratories Ltd., F. Hoffman-La Roche Ltd., Celltrion, Inc., and Biocon Limited are the key market players operating in global erythropoietin drugs market.

PUBLISHED: Jul, 2023 | FORMAT: PPT | LAST UPDATED: Jul, 2023 | PRICE: $3999

Rare Diseases

Italy Fabry Disease Drugs Market Analysis

Italy Fabry disease drugs market is projected to grow from $xx Mn in 2023 to $xx Mn by 2030, registering a CAGR of xx% during the forecast period of 2023 - 2030. The market for fabry disease drugs is growing rapidly as a result of increase in incidence and prevalence of fabry disease globally, increase in awareness about the disease globally, better diagnosis rates, improved access to treatment, development of new emerging therapies, orphan drug designations provided by regulatory body?s, increase in stratergic collaborations, rise in research and development activities and approval of promising pipeline products. Chiesi Farmaceutici SpA , Sanofi, Shire ,Takeda Pharmaceutical Company Limited, Amicus Therapeutics, Inc., JCR Pharmaceuticals, Moderna are the key market players operating in global fabry disease drugs market.

PUBLISHED: Jul, 2023 | FORMAT: PPT | LAST UPDATED: Jul, 2023 | PRICE: $3999

Rare Diseases

Italy Fibrodysplasia Ossificans Progressiva Drugs Market Analysis

Italy Fibrodysplasia Ossificans Progressiva Drugs Market is projected to grow from $xx Mn in 2023 to $xx Mn by 2030, registering a CAGR of xx% during the forecast period of 2023 ? 2030. The market for Fibrodysplasia Ossificans Progressiva Drugs is expanding as a result of growing incidence and prevalence of fibrodysplasia ossificans progressiva , increase in the number of R&D activities, increase in Partnerships and Collaborations between market players. Pfizer Inc., AstraZeneca, Limited, Regeneron Pharmaceuticals, Inc, Clementia Pharmaceuticals, Novartis are the top key market players operating in the global Fibrodysplasia Ossificans Progressiva Drugs market.

PUBLISHED: Jul, 2023 | FORMAT: PPT | LAST UPDATED: Jul, 2023 | PRICE: $3999

Rare Diseases

Italy Freidreich's Ataxia Market Analysis

Italy Freidreich?s Ataxia market is projected to grow from $xx Mn in 2023 to $xx Mn by 2030, registering a CAGR of xx% during the forecast period of 2023 - 2030. The market for Freidreich?s Ataxia is growing rapidly as a result of increase in research and developmental activities for diagnosis and treatment of freidreich?s ataxia, collaborations between academic institutions and industry partners and incentives provided in orphan drug designation by regulatory authorities. PTC Therapeutics, Design Therapeutics, Aurobindo Pharma Ltd., Sun Pharmaceutical Industries Ltd., Torrent Pharmaceuticals Ltd., Intas Pharmaceuticals Ltd., Larimar Therapeutics, Inc., Jupiter Neurosciences, Inc., Lexeo Therapeutics, Zydus Lifesciences Ltd., Cipla Limited, GlaxoSmithKline Plc., Reata Pharmaceuticals, Inc., and Retrotope Inc. are the key global market players operating in global freidreich?s Ataxia Market.

PUBLISHED: Jul, 2023 | FORMAT: PPT | LAST UPDATED: Jul, 2023 | PRICE: $3999

Rare Diseases

Italy Gaucher Disease Drugs Market Analysis

Italy Gaucher disease drugs market is projected to grow from $xx Mn in 2023 to $xx Mn by 2030, registering a CAGR of xx% during the forecast period of 2023 - 2030. The market for gaucher disease drugs is growing rapidly as a result of rising incidence and prevalence of gaucher disease, increasing infrastructure spending for healthcare, rising acceptance rate of early diagnosis, increasing number of government initiatives to raise awareness and an increasing number of approved therapies for the treatment of Gaucher disease. Aptalis Pharma, Abbott Laboratories, Genzyme Corporation, Pfizer Inc., GlaxoSmithKline (GSK), Eli Lilly and Company, AVROBIO, Shire Human Genetic Therapies, Inc., Anthera Pharmaceuticals, Inc., Enobia Pharma Inc., BioMarin Pharmaceutical Inc., Merck Serono, Zymenex A/S, and MedPro Rx are the top key players of gaucher disease drugs market.

PUBLISHED: Jul, 2023 | FORMAT: PPT | LAST UPDATED: Jul, 2023 | PRICE: $3999

Rare Diseases

Italy Guillain-Barre Syndrome (GBS) Drugs Market Analysis

Italy Guillain-Barre Syndrome (GBS) drugs market is projected to grow from $xx Mn in 2023 to $xx Mn by 2030, registering a CAGR of xx% during the forecast period of 2023 - 2030. The market for Guillain-Barre Syndrome (GBS) drugs is growing rapidly as a result of increase in the incidence and prevalence of the guillain-barre syndrome, advancements in technology and development in healthcare, support and funding by governments globally, rise in the geriatric population and increase in the prevalence of chikungunya and immune diseases like multiple sclerosis , increase in the approvals of immunoglobulins by regulatory bodies and increase in research and development activities by pharmaceutical companies. Alexion Pharmaceuticals Inc., Annexon Inc., Cellenkos Inc., Cresence AS, Akari Therapeutics Plc, Chugai Pharmaceutical Co Ltd are the key market players operating in global gullian barre syndrome drugs market.

PUBLISHED: Jul, 2023 | FORMAT: PPT | LAST UPDATED: Jul, 2023 | PRICE: $3999

Rare Diseases

Italy Hemophilia A Drugs Market Analysis

Italy Hemophilia A Drugs Market is projected to grow from $xx Mn in 2023 to $xx Mn by 2030, registering a CAGR of xx% during the forecast period of 2023 - 2030. The market for Hemophilia A is rising due to increase in incidence and prevalence of disease, increase in research and development activities, patent advocacy programmes, stratergic collaborations and partnerships. A lack of or failure with regard to clotting factor VIII characterises the rare inherited bleeding condition known as haemophilia A. It is the most prevalent form of haemophilia and primarily affects men, though it can also afflict women who carry the gene mutation. Hemophilia A market development goes beyond traditional markets, with a stronger emphasis on increasing access to care in developing markets. In areas where access to specialised care and therapies may be restricted, efforts are being made to improve diagnosis, treatment infrastructure, and pricing. Some of the notable companies operating in the Hemophilia A Drugs market include BioMarin Pharmaceutical Inc, Bayer AG, Pfizer Inc., Novo Nordisk A/S, F. Hoffmann-La Roche Ltd., Shire (now part of Takeda Pharmaceutical Company Limited), CSL Behring LLC, Sanofi S.A., Grifols S.A. and Octapharma AG.

PUBLISHED: Jul, 2023 | FORMAT: PPT | LAST UPDATED: Jul, 2023 | PRICE: $3999

Rare Diseases

Italy Hemophilia B Drugs Market Analysis

Italy Hemophilia B Drugs Market is projected to grow from $xx Mn in 2023 to $xx Mn by 2030, registering a CAGR of xx% during the forecast period of 2023 - 2030. The market for Hemophilia B is growing rapidly as a result of increasing patient awareness and diagnosis, advancements in treatment options, increasing research and development investments, stratergic collaborations and partnerships between research organizations and pharmaceutical companies. However, because Hemophilia B is less common than Hemophilia A, the market for therapies for this condition is smaller than it is for Hemophilia A. The rare genetic bleeding illness known as haemophilia B is brought on by a lack of or malfunction in the clotting factor IX. Takeda Pharmaceutical Company Limited (previously Shire), Pfizer Inc., F. Hoffmann-La Roche Ltd., Novo Nordisk A/S, CSL Behring LLC, Sanofi S.A., Grifols S.A., Octapharma AG, and others are notable market participants.

PUBLISHED: Jul, 2023 | FORMAT: PPT | LAST UPDATED: Jul, 2023 | PRICE: $3999

Rare Diseases

Italy Hemophilia Market Analysis

Italy Hemophilia Market is projected to grow from $xx Mn in 2023 to $xx Mn by 2030, registering a CAGR of xx% during the forecast period of 2023 - 2030. The ability of a person's blood to clot is impaired by haemophilia A and haemophilia B, two rare congenital lifelong bleeding disorders that can cause excessive bleeding and spontaneous bleeding into joints, which can cause joint damage and chronic pain and have a significant impact on quality of life. The rise in haemophilia prevalence, improvements in treatment technology, and supportive governmental activities for haemophilia management are all contributing factors to the market share growth for haemophilia treatments. In the "Global Hemophilia market," the following firms are described: Baxalta, CSL Behring, Pfizer, Inc., Bayer Healthcare, BioMarin Pharmaceutical, Inc., Biogen, Chugai Pharmaceutical Co., Novo Nordisk, Shire Plc., Baxter International, Inc., and Hospira Inc.

PUBLISHED: Jul, 2023 | FORMAT: PPT | LAST UPDATED: Jul, 2023 | PRICE: $3999

Rare Diseases

Italy Hemostasis Products Market Analysis

Italy Hemostasis Products market is projected to grow from $xx Mn in 2023 to $xx Mn by 2030, registering a CAGR of xx% during the forecast period of 2023 - 2030. The market for hemostasis products is growing rapidly as a result of rising prevalence of cardiovascular diseases worldwide due to adoption of unhealthy lifestyle, consumption of unhealthy food products and rising illnesses among the population, rising medical tourism, higher investments by government in research and development of hemostasis products, huge base of geriatric population coupled with large number of blood disorders patient population, increasing demand for minimally invasive surgeries, adoption of advanced hemostasis products by patients . Abbott Laboratories, Baxter International, CSL Behring, Hem Con Medical Technologies, Grifols, Johnson & Johnson, Medtronic, Pfizer, integra Life Sciences Corporation, C. R. Bard, Inc. are the key market players operating in global hemostasis products market.

PUBLISHED: Jul, 2023 | FORMAT: PPT | LAST UPDATED: Jul, 2023 | PRICE: $3999

Rare Diseases

Italy Hereditary Angioedema Drugs Market Analysis

Italy Hereditary Angioedema Drugs Market is projected to grow from $xx Mn in 2023 to $xx Mn by 2030, registering a CAGR of xx% during the forecast period of 2023 - 2030. The market for Hereditary Angioedema Drugs is growing as a result of Increasing Awareness and Diagnosis of disease, Advancements in Treatment Options, Technological Advancements and the regulatory authorities have designated numerous HAE therapies as orphan drugs as a result of this classification, pharmaceutical companies are given some incentives including financial advantages and prolonged exclusivity, which may promote investment in HAE R&D. This trend offers pharmaceutical businesses the chance to increase their market share, make research and development investments, and introduce novel treatments to various geographic areas. Hereditary angioedema therapies are being developed and produced by a number of international pharmaceutical companies (HAE). Takeda Pharmaceutical Company Limited, Inc., CSL Behring, Pharming Group NV, Ionis Pharmaceuticals, Pharvaris, Dyax Corp., Shire (now a part of Takeda), Attune Pharmaceuticals, Prometic Life Sciences Inc., KalVista Pharmaceuticals, and Biocryst are some of these organisations.

PUBLISHED: Jul, 2023 | FORMAT: PPT | LAST UPDATED: Jul, 2023 | PRICE: $3999

Rare Diseases

Italy Hodgkins Lymphoma Drugs Market Analysis

Italy Hodgkins Lymphoma Drugs Market is projected to grow from $xx Mn in 2023 to $xx Mn by 2030, registering a CAGR of xx% during the forecast period of 2023 - 2030.The market for Hodgkins Lymphoma Drugs is rising due to Increasing incidence of Hodgkin lymphoma, Extensive research and development activities, Growing adoption of immunotherapies, Increasing awareness and diagnosis about disease, Improved reimbursement policies and increased insurance coverage for cancer treatments along with growing availability of targeted therapies and combination therapies for Hodgkin Lymphoma Drugs. Bristol Myers Squibb, Merck & Co., Inc. (MSD), Takeda Pharmaceutical Company Limited, Roche Holding AG, Novartis AG, Pfizer Inc., AstraZeneca plc, Johnson & Johnson, AbbVie Inc., Celgene Corporation (a subsidiary of Bristol Myers Squibb), Amgen Inc., Gilead Sciences, Inc. are the global companies in Hodgkins Lymphoma Drugs market.

PUBLISHED: Jul, 2023 | FORMAT: PPT | LAST UPDATED: Jul, 2023 | PRICE: $3999

Rare Diseases

Italy Huntington's Disease Drugs Market Analysis

Italy Huntington's Disease Drugs Market is projected to grow from $xx Mn in 2023 to $xx Mn by 2030, registering a CAGR of xx% during the forecast period of 2023 ? 2030. The market for treating Huntington's disease is expanding due to a number of causes, including an increase in the disease's prevalence and a rise in the demand for modern drug types to treat the signs and symptoms of the disease especially rise in disease modifying therapies, incentives provided by regulatory authorities like orphan drug designations. Some of the key players in the global Huntington's Disease Drugs Market include Pfizer, Inc. Alnylam Pharmaceuticals Inc. Teva Pharmaceutical Industries Ltd. Neurocrine Biosciences, Inc. Ionis Pharmaceuticals, Vertex Pharmaceuticals Incorporated (U.S.), Elekta AB (Sweden), Alterity Drugs(Australia) and som biotech (spain).

PUBLISHED: Jul, 2023 | FORMAT: PPT | LAST UPDATED: Jul, 2023 | PRICE: $3999

subscribe to our newsletter
up